On Monday, shares of DocMorris AG (DOCM) hit strong gains on the SIX Swiss Exchange after the banking giant UBS upgraded the company’s rating.
In a research note issued Monday, UBS analyst Sebastian Vogel officially removed the Swiss online pharmacy from the bank’s high-conviction “Sell” list. The firm upgraded DocMorris’s equity rating to “Neutral” while raising its 12-month price target from CHF 4.00 to CHF 10.70.
It’s a significant change in the bank’s long-term outlook, as it considers a structural turnaround in DocMorris’s financial metrics and operating margins.
Why UBS Changed its View on DocMorris
The core driver behind the broker’s decision to drop its bearish posture is DocMorris’s “positively developing track record on its operating margin turnaround,” according to the analyst note.
-
Improved Sales Mix and Price Discipline:
Historically, aggressive pricing competition and extensive discounts on over-the-counter (OTC) personal care products heavily depressed the company’s retail profitability. However, UBS analysts highlight that DocMorris is now successfully engineering a more favorable sales mix. The e-pharmacy is retaining more cash per transaction by withdrawing from margin-eroding OTC promotions and targeting higher-value market segments.
-
Tighter Fiscal Controls and “AI-First” Cost Cutting
The company is also driving structural improvements through automated cost-management initiatives. DocMorris has accelerated its internal “AI-First” operational approach, which is designed to embed artificial intelligence into its customer service and logistical processes. These initiatives are expected to save at least CHF 15 million in annual structural costs and provide permanent upstream efficiencies.
-
Significantly Raised Profitability Outlook
These changes prompted UBS to overhaul its forecasts:
- The bank raised its fiscal 2026–2028 EBITDA margin projections to negative 1.2%, 0.9%, and 2.7%, respectively (from negative 1.8%, negative 0.4%, and 1.6%).
- By fiscal 2030, UBS now expects the adjusted group EBITDA margin to reach 7.3%, a dramatic improvement from the previously projected negative 4.4% for fiscal 2025.
- On the top line, UBS forecasts fiscal 2026 net sales at CHF 1,258 million (3% above consensus of CHF 1,222 million), fiscal 2027 at CHF 1,361 million (2% above consensus of CHF 1,334 million), and fiscal 2028 at CHF 1,454 million (in line with consensus).
- Adjusted EBITDA forecasts were also lifted: negative CHF 11 million in 2026 (vs. consensus of negative CHF 19 million), CHF 12 million in 2027 (vs. CHF 11 million), and CHF 39 million in 2028 (vs. CHF 37 million).
Bullish Market Share Assumptions
UBS raised its forecast for online pharmacies’ share of the German prescription drug market to 3.3% by fiscal 2030 (from 3%), citing DocMorris’s strong momentum. The company’s own projected share of that online prescription segment was increased to 36% by 2030 (from 35.5%), supported by first-half fiscal 2026 organic growth of about 38% in the German Rx market.
OTC segment forecasts were left unchanged, with DocMorris’s market share expected to decline to around 25% by 2030 (from 35% in fiscal 2025) due to rising competition from traditional drugstore and personal care chains.
Market Response
The upgrade triggered immediate buying momentum to come in as soon as the bell rang on Monday. DocMorris stock opened the session up at CHF 11.05 before rallying intraday to a session high of CHF 11.20, marking an approximate single-day peak gain of 5.07% against its previous close of CHF 10.66.
The stock traded at a price of CHF 10.71 near midday trading on the Swiss exchange. Trading volume jumped well over average levels with the institutional algorithms adapting to the new valuation ranges.
A Growing Consensus Across the Street
The shift in sentiment at UBS is not an isolated event; it represents a significant change in views among major bearish analysts covering the stock. Just one week prior, Deutsche Bank analyst Jan Koch triggered a strong 17% single-day rally by upgrading DocMorris directly to a “Buy” and setting a street-high price target of CHF 11.50.
Deutsche Bank noted that regulatory changes in Germany on the eRx (electronic prescription ecosystem) have significantly reduced both execution and funding risks.
Shortly after that upgrade, DocMorris confirmed the market’s optimism through its Q2 trading scorecard. The firm reported revenue increase of 15.2% in local currency to CHF 309.7 million, largely driven by a substantial 46% year-over-year surge in German prescription drug sales.
Both Deutsche Bank and UBS have raised their forecast, reinforcing confidence in DocMorris’s long-term turnaround ahead of its full half-year financial results on 19 August 2026.
